Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Targeted therapies and non-small-cell lung cancer: new developments.

Gridelli C.

Curr Opin Oncol. 2007 Mar;19(2):75-7. Review. No abstract available.

PMID:
17272976
2.

Recent developments of targeted therapies in the treatment of non-small cell lung cancer.

Rossi A, Maione P, Colantuoni G, Ferrara C, Rossi E, Guerriero C, Nicolella D, Falanga M, Palazzolo G, Gridelli C.

Curr Drug Discov Technol. 2009 Jun;6(2):91-102. Review.

PMID:
19519336
3.

Combined targeted therapies in non-small cell lung cancer: a winner strategy?

Cascone T, Gridelli C, Ciardiello F.

Curr Opin Oncol. 2007 Mar;19(2):98-102. Review.

PMID:
17272980
5.

Targeted therapies and non-small-cell lung cancer: work in progress?

Gridelli C.

Curr Opin Oncol. 2006 Mar;18(2):132-4. Review. No abstract available.

PMID:
16462181
6.

Targeted therapies in the treatment of non small cell lung cancer: reality and hopes.

Gridelli C.

Curr Opin Oncol. 2004 Mar;16(2):126-9. Review. No abstract available.

PMID:
15075903
7.

Targeted therapies in lung cancer.

Pirker R, Filipits M.

Curr Pharm Des. 2009;15(2):188-206.

PMID:
19149612
8.

Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.

Kotteas EA, Charpidou AG, Syrigos KN.

Anticancer Drugs. 2010 Feb;21(2):151-68. doi: 10.1097/CAD.0b013e328334da02. Review.

PMID:
20016368
9.

Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

Pennell NA, Lynch TJ Jr.

Oncologist. 2009 Apr;14(4):399-411. doi: 10.1634/theoncologist.2008-0276. Epub 2009 Apr 8. Review.

10.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Subramanian J, Morgensztern D, Govindan R.

Clin Lung Cancer. 2010 Sep 1;11(5):311-9. doi: 10.3816/CLC.2010.n.039. Review.

PMID:
20837456
11.

Inhibition of angiogenesis in the treatment of non-small cell lung cancer.

Keedy VL, Sandler AB.

Cancer Sci. 2007 Dec;98(12):1825-30. Epub 2007 Sep 24. Review.

12.

[Targeted therapies. New hopes, new challenges].

Barlési F.

Rev Mal Respir. 2008 Jun;25(6):661-2. French. No abstract available.

PMID:
18772823
13.

[Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].

Zhou CC, Deng XF.

Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):138-40. Review. Chinese. No abstract available.

PMID:
17445479
14.

Targeted therapy for non-small cell lung cancer.

Toloza EM, D'Amico TA.

Semin Thorac Cardiovasc Surg. 2005 Fall;17(3):199-204. Review.

PMID:
16253823
15.

Second-generation epidermal growth factor tyrosine kinase inhibitors in non-small cell lung cancer.

Mukherji D, Spicer J.

Expert Opin Investig Drugs. 2009 Mar;18(3):293-301. doi: 10.1517/13543780902762843 . Review.

PMID:
19243280
16.

Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer.

Socinski MA.

Cancer Treat Rev. 2011 Dec;37(8):611-7. doi: 10.1016/j.ctrv.2011.04.003. Epub 2011 Jun 8. Review.

PMID:
21641723
17.

[Radiotherapy and targeted therapies in non-small-cell lung cancer].

Girard N, Mornex F.

Bull Cancer. 2009 Mar;96(3):311-9. doi: 10.1684/bdc.2009.0837. Review. French.

18.

Epidermal growth factor tyrosine kinase inhibitors (EGFR TKIs) and economics.

van Zandwijk N.

Lung Cancer. 2006 Jan;51(1):137-8. Epub 2005 Dec 1. No abstract available.

PMID:
16324767
19.

[State of the art in chemoradiotherapy combinations and potential role in targeting therapy approaches in nonsmall cell lung cancer].

Chargari C, Deutsch E, Le Péchoux C, Magné N.

Cancer Radiother. 2009 Apr;13(2):114-22. doi: 10.1016/j.canrad.2008.08.273. Epub 2009 Jan 20. French.

PMID:
19157950
20.

Developing targeted therapies for lung cancer.

Gandara DR.

Clin Adv Hematol Oncol. 2003 Nov;1(11):648-9, 690. No abstract available.

PMID:
16258461

Supplemental Content

Support Center